Compare OMH & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | CMND |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 1.4M |
| IPO Year | 2022 | 2021 |
| Metric | OMH | CMND |
|---|---|---|
| Price | $1.00 | $0.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.6K | ★ 6.9M |
| Earning Date | 05-08-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.07 |
| 52 Week High | $4.33 | $3.25 |
| Indicator | OMH | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 43.40 |
| Support Level | $0.75 | $0.59 |
| Resistance Level | $1.36 | $1.18 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 30.64 | 17.07 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.